GANX · NASDAQ
Gain Therapeutics (GANX) Stock Price & Fundamentals
Gain Therapeutics (GANX) closed at $625.62 on Oct 9, 2026, up 1.44% from the previous close of $616.73.
Share price, past year
1Y +28.03%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $625.62 |
| Sep 30, 2026 | $601.10 |
| Aug 31, 2026 | $593.25 |
| Jul 31, 2026 | $582.60 |
| Jun 30, 2026 | $576.63 |
| May 29, 2026 | $581.46 |
| Apr 30, 2026 | $553.78 |
| Mar 31, 2026 | $572.99 |
| Feb 27, 2026 | $548.88 |
| Jan 30, 2026 | $535.74 |
| Dec 31, 2025 | $544.60 |
| Nov 28, 2025 | $483.99 |
| Oct 31, 2025 | $486.20 |
Key statistics
- Market cap
- $27.11B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.50
- Revenue (TTM)
- —
- Net income (TTM)
- −$20.11M
- Shares outstanding
- 43.3M
- Dividend yield
- —
- 52-week range
- $479.62 – $625.62
Gain Therapeutics's market cap is $27.11B, based on a share price of $625.62 and 43.3M shares outstanding as of Jun 30, 2026.
Financials
Gain Therapeutics reported revenue of $55.18K for fiscal 2023, down 60.62% from fiscal 2022.
Gain Therapeutics reported a net loss of $20.16M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2023ended Dec 31, 2023 | $55.18K | −60.6% | −$22.27M | −40,354.3% | −$1.71 | — |
| FY2022ended Dec 31, 2022 | $140.11K | −15.1% | −$17.59M | −12,555.1% | −$1.48 | — |
| FY2021ended Dec 31, 2021 | $164.99K | +471.3% | −$13.89M | −8,418.9% | −$1.37 | −$12.46M |
| FY2020ended Dec 31, 2020 | $28.88K | — | −$3.58M | −12,387.7% | −$1.33 | −$3.26M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q1 FY2023ended Mar 31, 2023 | $55.18K | — | — |
| Q2 FY2022ended Jun 30, 2022 | $95.10K | — | — |
| Q1 FY2022ended Mar 31, 2022 | $45.01K | — | — |
| Q4 FY2021ended Dec 31, 2021 | $43.21K | — | — |
| Q3 FY2021ended Sep 30, 2021 | $27.35K | — | — |
| Q2 FY2021ended Jun 30, 2021 | $89.17K | — | — |
| Q1 FY2021ended Mar 31, 2021 | $5.27K | — | — |
| Q4 FY2020ended Dec 31, 2020 | $9.14K | — | — |
Company profile
- Name
- Gain Therapeutics, Inc.
- Ticker
- GANX
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 4800 Hampden Lane, Suite 200, Bethesda, MD 20814
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001819411
Recent SEC filings
- Oct 1, 2026
- Sep 28, 2026
- Aug 11, 2026
- Aug 11, 2026
- Jul 16, 2026
- Jun 29, 2026
- Jun 25, 2026
- May 26, 2026
Frequently asked questions
What is Gain Therapeutics's stock price?
Gain Therapeutics (GANX) closed at $625.62 on Oct 9, 2026, up 1.44% from the previous close of $616.73.
What is Gain Therapeutics's market cap?
Gain Therapeutics's market cap is $27.11B, based on a share price of $625.62 and 43.3M shares outstanding as of Jun 30, 2026.
How much revenue does Gain Therapeutics make?
Gain Therapeutics reported revenue of $55.18K for fiscal 2023, down 60.62% from fiscal 2022.
Does Gain Therapeutics pay a dividend?
Gain Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Gain Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures